Chia Tai Reports July Revenue of NT$1.902 Billion, Record High for the Period, with Backlog at Historic High to Fuel Q3 Operations

Chia Tai (6472-TW) announced today (10th) its July revenue reached NT$1.902 billion. While down 17.23% month-on-month, it marked a 5.77% year-on-year increase, setting a new historical high for the same period. Chia Tai stated that with backlog for the next 12 months continuing at historic highs, and the completion of the acquisition and integration of the Rockville large-molecule biologics CDMO facility in July, it holds a positive outlook for Q3 operations.

Chia Tai’s July revenue was NT$1.902 billion, down 17.23% MoM and up 5.77% YoY. Cumulative revenue for the first seven months of the year reached NT$11.794 billion, down 0.08% YoY.

Chia Tai explained that the revenue decline was influenced by customer shipment schedules at its Zhunan and Canada plants, as well as reduced production at its Maryland injectables facility. The Maryland plant is executing quality improvement projects in response to U.S. FDA recommendations regarding passive RABS (Passive Restricted Access Barrier Systems) on legacy production lines, operating at reduced capacity during this period, with some orders deferred to early August. Despite seasonal factors and order deferrals, July revenue still achieved a record high for the period, with overall business momentum remaining stable.

The company further emphasized that end-customer demand and overall order trends remain unchanged, with backlog for the next 12 months continuing at historic highs. With the addition of the Rockville large-molecule biologics CDMO facility—acquired and integrated into the group in July—both current backlog and volume production momentum exceed those of the same period last year. The inclusion of the Rockville facility strengthens Chia Tai’s U.S. footprint and CDMO service capabilities across small molecules, sterile formulations, and large-molecule biologics, bolstering expectations for Q3 performance.

In global sales, Chia Tai noted that Upsher-Smith’s orphan disease specialty drugs continue to see rising performance, while market prices for the gastroesophageal reflux disease (GERD) generic drug DLS are gradually stabilizing. Increased procurement momentum from government channels is driving overall product portfolio improvement.

Additionally, in consumer healthcare, Weider Global Nutrition (Weider), consolidated into the financial statements since May, has shown stable operations. With the U.S. retail peak season approaching in September and October, future sales momentum is expected to strengthen further.